Outcomes Of Surgically Treated N2-Positive Non-Small Cell Lung Cancer


  • Joana Rei Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal https://orcid.org/0000-0002-0014-1968
  • Patrícia Castro Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal
  • Miguel Guerra Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal
  • José Miranda Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal




Surgery, NSCLC, Staging, Lung Cancer


Introduction: The role of surgery in the treatment of stage IIB/IIIA lung cancer is still a matter of debate. To assess the outcomes of N2-positive patients, we performed a retrospective 10-year study including all patients with histologically proven N2 disease submitted to lung resection surgery by the same surgical team in three different hospitals.
Materials and Methods: Demographic, clinical, surgical and survival data were collected from patients’ clinical registries. Patients were divided into groups according to evidence of neoadjuvant chemotherapy and number of positive N2 stations. Outcomes regarding survival time within and between groups were calculated and compared.
Results: Sixty-four patients were included in our study, with a mean age of 62,2 years. Surgery was performed by uniportal VATS in 43.8% of cases. A mean of 3 nodal stations were sampled and 35 patients (54.7%) had one single positive N2 station. Post-operative complications occurred in 27% of patients but no post-operative mortality was recorded. Twenty-seven patients (42.2%) were submitted to neoadjuvant chemotherapy. Survival time within this group was of 67,7±10,5 months, which was not statistically different from those who performed upfront surgery (survival time 48±5,2 months). Patients with single N2 positive stations had a longer survival time than those with multiple N2 positive stations (p<0.05). Within the group of patients with single N2 disease (n=35), no difference in survival time was found regarding neoadjuvant therapy.
Conclusions: Surgery is effective in selected patients with N2 disease, in particular those with single-N2 positive stations. Neoadjuvant chemotherapy may not grant survival benefit. Adequate pre-operative staging is essential.


Download data is not yet available.


Jeremić B. Induction Therapies Plus Surgery Versus Exclusive Radiochemotherapy in Stage IIIA/N2 Non-Small Cell Lung Cancer (NSCLC). Am J Clin Oncol. 2018;41(3):267-73.

Behera M, Steuer CE, Liu Y, Fernandez F, Fu C, Higgins KA, et al. Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis. Oncologist. 2020;25(6):e964-e75.

Li X, Li X, Fu X, Liu L, Liu Y, Zhao H, et al. Survival benefit of skip metastases in surgically resected N2 non-small cell lung cancer: A multicenter observational study of a large cohort of the Chinese patients. Eur J Surg Oncol. 2020;46(10 Pt A):1874-81.

Evison M, Clive A, Castle L, Powell H, Thomas R, Buttery R, et al. Resectable Clinical N2 Non-Small Cell Lung Cancer; What Is the Optimal Treatment Strategy? An Update by the British Thoracic Society Lung Cancer Specialist Advisory Group. J Thorac Oncol. 2017;12(9):1434-41.

Shien K, Toyooka S. Role of surgery in N2 NSCLC: pros. Jpn J Clin Oncol. 2016;46(12):1168-73.

AJCC Cancer Staging Manual. 8 ed: Springer Cham; 2017. XVII, 1032 p.

Kirmani BH, Volpi S, Aresu G, Peryt A, Win T, Coonar AS. Long term and disease-free survival following surgical resection of occult N2 lung cancer. J Thorac Dis. 2018;10(8):4806-11.

Sanchez-Lorente D, Guzman R, Boada M, Guirao A, Carriel N, Molins L. N2 disease in non-small-cell lung cancer: straight to surgery? Future Oncol. 2018;14(6s):13-6.

Zhao Y, Wang W, Liang H, Yang CJ, D'Amico T, Ng CSH, et al. The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis. Ann Thorac Surg. 2019;107(6):1866-75.

McElnay PJ, Choong A, Jordan E, Song F, Lim E. Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials. Thorax. 2015;70(8):764-8.

Kruser TJ, Mohindra N, DeCamp MM. One size does not fit all: Nuances in postoperative N2 non-small cell lung cancer management. J Thorac Cardiovasc Surg. 2018;156(1):370-3.

Bertoglio P, Ricciardi S, Alì G, Aprile V, Korasidis S, Palmiero G, et al. N2 lung cancer is not all the same: an analysis of different prognostic groups. Interact Cardiovasc Thorac Surg. 2018;27(5):720-6.

Gillaspie EA, Wigle DA. Management of Stage IIIA (N2) Non-Small Cell Lung Cancer. Thorac Surg Clin. 2016;26(3):271-85. 14. Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Tho-

rac Surg. 2008;86(3):912-20; discussion -20.

Couñago F, Montemuiño S, Martin M, Taboada B, Calvo-Crespo P, Samper-Ots MP, et al. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Clin Transl Oncol. 2019;21(6):735-44.

Massard G, Renaud S, Reeb J, Santelmo N, Olland A, Falcoz PE. N2-IIIA non-small cell lung cancer: a plea for surgery! J

Thorac Dis. 2016;8(Suppl 11):S849-S54.




How to Cite

Rei J, Castro P, Guerra M, Miranda J. Outcomes Of Surgically Treated N2-Positive Non-Small Cell Lung Cancer. Rev Port Cir Cardiotorac Vasc [Internet]. 2024 Feb. 9 [cited 2024 Jun. 13];30(4):23-9. Available from: https://pjctvs.com/index.php/journal/article/view/320



Original Articles


Most read articles by the same author(s)

1 2 > >>